Experimental Treatment for Black Wolf Fever

Experimental Treatment for Black Wolf Fever is a sequence of high-stakes medical trials in which Hohsalle, Milalle, and Limuelle try to make treatment possible for patients facing mittsual, a disease for which death can otherwise be inevitable. Their work moves from identifying the disease and its agents to testing an anti-mittsual medicine, while each decision exposes the tension between a possible chance of survival and a treatment whose risks remain uncertain.

Origins and Medical Framework

The treatment depends on a different account of illness from the doctrine followed by Zol’s priest-doctors. Under the Pure Heart Creed, physicians were regarded as “the fingers of the god”; when they declared a condition incurable, accepted practice was to leave the patient to divine care and offer only medicines that eased the dying process. Limuelle and Hohsalle had already challenged that boundary by curing Emperor Natalu’s wife with Otawalle medicine, provoking opposition from the priest-doctors and alerting the Zolian aristocracy to the reach of their methods.

In the investigation at the salt mine, Hohsalle examined bodies bearing dog-bite marks and rashes, evidence that the deaths were not simply the result of poisoned food. He explained that black wolf fever could pass through wolves and ossam, as well as through fleas or ticks that had bitten infected animals or people. Cold and frost made fleas mostly dormant, but did not eliminate them: they could remain active through winter in warm places, including an animal’s body or near a hearth. The distinction mattered to both diagnosis and the assessment of how infection might spread.

The bodies also offered material for research. Milalle described three possible lines of investigation: identify the disease agents and weaken or kill them; find substances that suppress or eliminate the disease; and search for antibodies produced by victims’ bodies that might be used to make a serum. Hohsalle’s explanation of the body’s defenses made the preventive logic intelligible to Yotalu: weakened agents could teach the body to recognize a particular disease before encountering it in its full strength. Limuelle had discovered the rationale for introducing weakened agents, while Hohsalle developed an injectable medicine based on that work. Hohsalle cautioned that the treatment burdened the body and could, in some cases, cause a violent reaction and severe mental impairment; the twelve patients tried so far had survived without that complication, but the number was too small to establish safety.

Treating Izam

When Izam’s condition raised the possibility of an intervention before convulsions began, Limuelle proposed Kokalu, a potent sedative. Milalle connected the approach to an earlier rabies case: Limuelle had saved a young girl by using bossa, which had the same effect, to suppress convulsions by rendering her unconscious and shutting out the brain’s commands to the body. The rationale was to prevent the tremors from arresting breathing and give the body time to fight the disease agents. Limuelle stressed that the sedative had to be administered before convulsions began, or it would be useless.

Izam fell into a coma after receiving Kokalu, but continued to breathe. Hohsalle said that the other drugs had so far suppressed symptoms for only about a day and had not saved the patients who received them. Because Milalle had prepared ample anti-mittsual medicine, Limuelle directed Hohsalle to keep administering it while Izam was sedated. The treatment was a gamble: the boy’s slight body might not withstand the struggle, but sedation and repeated medicine offered a different possibility from the outcomes of the earlier patients. Izam did not develop convulsions that night, allowing Hohsalle and Milalle to rest after entrusting his care to Limuelle.

Consent and Risk

The later trials make the danger explicit rather than treating the new medicine as a guaranteed remedy. Mazai, who had been bitten by a dog infected with mittsual, developed a sore throat and asked for an injection. Milalle had refused him, and Hohsalle explained that the medicine could cause a severe allergic reaction, even one that stopped his breathing. Mazai understood that the remedy might also produce other harmful effects, but argued that the disease itself gave him a high chance of death. He did not want to leave his wife and children; he asked to accept the risk of a treatment that might improve his prospects, however slightly. Hohsalle did not simply proceed: he sent Makokan to ask Milalle to prepare what would be needed to respond to an allergic reaction.

The decisions involving Sulumina and Olimu likewise involved family consent and medical caution. Yotalu asked Hohsalle to treat them, but Hohsalle emphasized that the medicine’s burden on the body made its outcome difficult to predict. Limuelle proposed obtaining Yotalu’s permission before proceeding, since Sulumina was the wife of Governor Ohan’s younger son and Olimu his grandson. Sulumina agreed. Limuelle returned with supplies for a possible reaction; although she had asked to receive the injection first, she and Olimu were visibly apprehensive when faced with the syringe. Olimu’s fear was met with reassurance, and Limuelle administered the carefully measured serum to him.

Olimu showed no signs of an allergic reaction, though the injection site swelled more than Mazai’s. Sulumina’s response was sharply different: soon after receiving the medicine, she struggled to breathe. Hohsalle and Milalle acted in coordination while Limuelle injected another medicine; Hohsalle positioned her to secure her air passages, and Milalle used a sprayer in her throat. Hohsalle reassured Olimu that the medicine Limuelle had given was effective and that his mother was already recovering. Mana recognized what that emergency medicine was made from, but Hohsalle and Milalle said nothing in response to his expression.

Outcomes and Limits

Mazai also developed a rash and lost consciousness. Hohsalle judged the rash likely to be a reaction to the new medicine and considered the loss of consciousness the greater concern. That night Mazai convulsed, but the episode was milder than those of other patients, ended quickly, and did not become life-threatening. The following morning Olimu and Sulumina also became stuporous and then convulsed; their episodes, too, were not critical. After a long, deep sleep of about half a day, both woke disoriented. Milalle told Olimu that he would be fine and could not hide her joy as she patted his shoulder.

These results mark a meaningful but limited advance. The treatment did not spare its recipients from reactions or from the frightening progression of symptoms, and the evidence remained too uncertain to promise safety in advance. But Mazai’s convulsions were not fatal, and Olimu and Sulumina recovered from their episodes. Against a disease whose symptoms had previously proved deadly, those outcomes gave the experimental approach a measure of hope without resolving its risks.

The contrast between the clinical scenes and the competing ideas of illness remains central. Mana declined Hohsalle’s offer to see the tiny organisms believed to cause disease. For Mana, a priest-doctor of the Pure Heart Creed, the patient’s body already made the relevant problem visible: what mattered was recognizing defilement through its effects and removing the obstacles to living well, not identifying its particular microscopic cause. His position differs from Hohsalle’s investigation of agents, weakened preparations, and serum, yet both are framed around attending to patients. The treatment’s significance lies not in a claim of certain mastery, but in the effort to act on incomplete knowledge when leaving a patient untreated could mean death.